Pharmaceutical labs commit significant capital to acquiring cutting-edge equipment. However, these sophisticated instruments often remain idle, resulting in a considerable financial burden. Underutilized equipment represents a loss ofresources and can adversely impact a lab's throughput. Quantifying the scope of this financial impact is essential f